Neuroleptic malignant syndrome in a patient with stable dose of olanzapine

Abstract

Neuroleptic malignant syndrome (NMS), a potentially fatal consequence due to typical neuroleptics, has been described so far. In the past few years, there has been increased use of atypical antipsychotic drugs. Cases of NMS related to atypical neuroleptics, such as olanzapine, are less common in spite of increasing cases reported in literatures. Here, we report a case of NMS in a patient with bipolar affective disorder on maintenance treatment with 5 mg olanzapine for the last 7 year. He was successfully treated with bromocriptine and discharged in stable condition in 10 days.

Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature

“…While NMS is more common in typical antipsychotics, several reports showed that atypical antipsychotics, more specifically olanzapine, can give rise to NMS. [8][9][10][11][12][13][14][15] It has also been found that NMDA receptors control the release of dopamine through direct synaptic action on dopaminergic terminals. Decreased NMDA receptors can affect dopaminergic transmission, 1,16 NMDA receptor antibodies block the NMDA receptor in the presynaptic gamma-aminobutyric acid neurons of the thalamus and frontal cortex.…”